



Scientific Track

Monday, November 30 Registration and Welcome Reception		
Time	Event/Title	Speaker/Participants
1800 - 1930	Welcome reception and pre-registration	All conference participants

Scientific Track At-A-Glance

Dec 1 - Day 1 DLB Review & Update

0730 - 0800	Overview
0800 - 0930	Clinical
1000 - 1130	Imaging/Biomarkers
1130 - 1300	Lunch break
1300 - 1445	Neuropathology/Genetics/Basic Science
1515 - 1645	Therapeutics
1645 -	Dinner Activities/Recreation/Leisure Time

Dec 3 - Day 3 New Research in DLB II

0800 - 0945	Neuropathology/Molecular Biology
1015 - 1215	Genetics/Biofluid Markers
1215 - 1330	Lunch break
1330 - 1500	Novel Therapeutics
1530 - 1700	Working Groups or Leisure Time
1700 - 1830	Poster Session
1830 -	Dinner Activities/Recreation/Leisure
1900 - 2200	Clinical-Neuroimaging-Pathology Symposium

Dec 2 - Day 2 New Research in DLB I

0800 - 0945	Clinical I – Cognitive/Neuropsychology
1015 - 1200	Clinical II – Motor/Sleep/Other
1200 - 1315	Lunch break
1315 - 1500	Imaging
1530 - 1700	Working Groups or Leisure Time
1700 - 1830	Poster Session
1830 -	Dinner Activities/Recreation/Leisure Time

Dec 4 - Day 4 Hot Topics/Controversies/Harmony

0730 - 0830	Hot Topics
0900 - 1030	Controversies
1100 - 1245	Global DLB Harmonization
1245 - 1330	Lunch break
1330 - 1600	Working Groups or Leisure Time

Scientific Track Program

(continued on the following pages)

Tuesday, December 1 – Day 1
DLB Review and Update
(Optional Day for Patient and Care Partner Track Participants)

Time	Event/Title	Speaker/Participants
Overview		
0730 - 0745	Conference overview	Organizers
0745 - 0800	A caregiver's perspective of DLB	Angela Taylor LBDA
Session 1: DLB Update - Clinical		
Session Co-Chairs: Brad Boeve, Mayo Clinic Rochester; Jim Galvin, Florida Atlantic University		
0800 - 0820	DLB history, differential diagnosis and diagnostic features	Ian McKeith Newcastle University
0820 - 0840	Key clinical, epidemiologic, neuropsychological, and imaging features of DLB	Brad Boeve Mayo Clinic Rochester
0840 - 0900	DLB: Tools for the clinician	Jim Galvin Florida Atlantic University
0900 - 0930	Discussion	Panel and audience
0930 - 1000	<i>Break</i>	
Session 2: DLB Update – Imaging/Biomarkers		
Session Co-Chairs: John O'Brien, Cambridge University; John-Paul Taylor, Newcastle University		
1000 - 1020	Cross-sectional and longitudinal structural imaging studies in DLB	John O'Brien Cambridge University
1020 - 1040	Functional imaging changes in DLB	Nicolas Bohnen University of Michigan
1040 - 1100	Electrophysiologic correlates of DLB	John-Paul Taylor Newcastle University
1100 - 1130	Discussion	Panel and audience
1130 - 1300	<i>Lunch</i>	
Session 3: DLB Update – Neuropathology/Genetics/Basic Science		
Session Co-Chairs: Dennis Dickson, Mayo Clinic Florida; Jose Bras, University College London		
1300 - 1320	Historical perspective of DLB and Lewy body disease	Kenji Kosaka Yokohama Univ.
1320 - 1340	Neuropathologic perspectives of Lewy body disease	Dennis Dickson Mayo Clinic Florida
1340 - 1400	Genetic perspectives of DLB	Jose Bras University College London
1400 - 1420	Molecular biology and animal models of Lewy body disease	Virginia Lee University of Pennsylvania
1420 - 1445	Discussion	Panel and audience
1445 - 1515	<i>Break</i>	
Session 4: DLB Update – Therapeutics		
Session Co-Chairs: Ian McKeith, Newcastle University; Doug Galasko, UCSD		
1515 - 1535	Cholinesterase inhibitors and memantine	Zuzana Walker University College London
1535 - 1555	Antipsychotics	Clive Ballard King's College London
1555 - 1615	Antiparkinsonism agents	David Burn Newcastle University
1615 - 1645	Discussion	Panel and audience
1645 -	Dinner Activities/Recreation/Leisure Time	Participants to choose

Wednesday, December 2 – Day 2
New Research in DLB I

Time	Event/Title	Speaker/Participants
0700 - 0800	Breakfast	Participants
Session 5: Clinical I		
Session Co-Chairs: David Salmon, UCSD; Tanis Ferman, Mayo Clinic Florida		
0800 - 0820	Cognitive neuroscience approach to DLB	David Salmon UC San Diego
0820 - 0840	Visual hallucinations in DLB	Dominic Ffytche King's College London
0840 - 0855	Disease trajectory and cognitive profiles of three pathologic subtypes of DLB	Tanis Ferman Mayo Clinic Florida
0855 - 0910	Does abnormal ventral visual stream function underlie recurrent complex visual hallucinations in dementia with Lewy bodies?	Christopher Morris Newcastle University
0910 - 0925	Neuropsychological performance identify impending dementia with Lewy bodies in rapid eye movement sleep behavior disorder	Daphne Genier Marchand Univ du Québec à Montréal
0925 - 0945	Discussion	Speakers and audience
0945 - 1015	<i>Break</i>	
Session 6: Clinical II		
Session Co-Chairs: Ron Postuma, McGill University; John Duda, University of Pennsylvania		
1015 - 1035	Sleep issues in DLB, including prodromal DLB	Alex Iranzo Hospital Clinic Barcelona
1035 - 1055	Motor and autonomic issues in DLB, including prodromal DLB	Ron Postuma McGill University
1055 - 1110	Prodromal symptoms in dementia with Lewy bodies: The Newcastle LewyPro Study	Paul Donaghy Newcastle University
1110 - 1125	Cognition in at-risk Lewy body disease	Daniel Weintraub University of Pennsylvania
1125 - 1140	Prodromal electroencephalogram slowing in rapid eye movement sleep behavior disorder	Jessica Rodriguez-Brazete Univ du Québec à Montréal
1140 - 1200	Discussion	Speakers and audience
1200 - 1315	<i>Lunch</i>	
Session 7: Imaging		
Session Co-Chairs: Kejal Kantarci, Mayo Clinic Rochester; Alan Thomas, Newcastle, University		
1315 - 1335	Imaging-pathologic correlations in DLB	Kejal Kantarci Mayo Clinic Rochester
1335 - 1355	Imaging in prodromal DLB	Alan Thomas Newcastle University
1355 - 1410	Predicting survival in dementia with Lewy bodies with hippocampal volumetry	Jon Graff-Radford Mayo Clinic Rochester
1410 - 1425	Quantitative correlation between cardiac meta-iodobenzylguanidine (MIBG) uptake and remaining axons of the cardiac sympathetic nerve in Lewy body disease	Satoshi Orimo Kanto Central Hospital
1425 - 1440	PiB and T807 PET imaging of amyloid and tau pathology in dementia with Lewy bodies	Stephen Gomperts Mass. General Hospital
1440 - 1500	Discussion	Speakers and audience
1500 - 1530	<i>Break</i>	
Session 8: Working Groups or Recreation/Leisure Time		
1530 - 1700	Working Groups	Working group staff
1530 - 1700	Recreation/Leisure Time	All other participants
1700 - 1830	Poster Session	All conference participants
1830 -	Dinner Activities/Recreation/Leisure Time	Participants to choose

Thursday, December 3 – Day 3
New Research in DLB II

Time	Event/Title	Speaker/Participants
0700 - 0800	Breakfast	Participants
Session 9: Neuropathology/Molecular Biology		
Session Co-Chairs: Glenda Halliday, University of New South Wales; Patrik Brundin, Van Andel Institute		
0800 - 0820	Models of pathogenesis	Glenda Halliday Univ. New South Wales
0820 - 0840	Cell to cell transmission of synucleinopathies	Patrik Brundin Van Andel Institute
0840 - 0855	Pathological and synaptic correlates of cognition and behaviour in Lewy body dementia	Paul Francis King's College London
0855 - 0910	Prevalence of esophageal and submandibular gland synucleinopathy in dementia with Lewy bodies and other Lewy body disorders	Thomas Beach Banner Sun Health Research Institute
0910 - 0925	The role of the visual thalamus in the visual hallucinations in dementia with Lewy bodies	Daniel Erskine Newcastle University
0925 - 0945	Discussion	Speakers and audience
0945 - 1015	<i>Break</i>	
Session 10: Genetics/Biofluid Markers		
Session Co-Chairs: Andrew Singleton, National Institute on Aging; Omar El-Agnaf, UAE University		
1015 - 1035	alpha-synuclein oligomers as a biomarker	Omar El-Agnaf United Arab Emirates Univ.
1035 - 1055	Blood-based (protein) biomarker efforts in Parkinson's disease and Alzheimer's disease: Potential applicability to DLB	Alice Chen-Plotkin University of Pennsylvania
1055 - 1110	APOE ε4 is associated with risk of dementia with Lewy bodies irrespective of severity of Alzheimer's disease pathology	Melissa Murray Mayo Clinic Florida
1110 - 1125	A cluster of structural variants in intron 4 of SNCA gene confers risk for Lewy Body pathology in Alzheimer's disease and affects SNCA expression profiles	Ornit Chiba-Falek Duke University
1125 - 1140	Comparative genetic analysis of dementia with Lewy bodies and Parkinson's disease with dementia	Debby Tsuang Univ. of Washington
1140 - 1155	Dementia with Lewy bodies and Alzheimer's disease: an unfortunate couple	Marlijn de Beer The Hague & VU Univ Alzheimer Ctr
1155 - 1215	Discussion	Speakers and audience
1215 - 1330	<i>Lunch</i>	
Session 11: Novel Therapeutics		
Session Co-Chairs: Eliezer Masliah, UCSD; Jim Leverenz, Cleveland Clinic		
1330 - 1350	Novel therapeutics: Clues from model systems	Eliezer Masliah UC San Diego
1350 - 1410	Novel therapeutics: Human trials and next steps	Jim Leverenz Cleveland Clinic
1410 - 1425	Efficacy results of a phase 2b study of RVT-101, a neurotransmitter-targeted therapy, in mild-to-moderate Alzheimer's disease	Lawrence Friedhoff Axovant Sciences, Inc.
1425 - 1440	Efficacy, safety and tolerability of armodafinil therapy for hypersomnia associated with DLB: A pilot study	Maria Lapid Mayo Clinic Rochester
1440 - 1500	Discussion	Speakers and audience
1500 - 1530	<i>Break</i>	
Session 12: Working Groups or Recreation/Leisure Time		
1530 - 1700	Working Groups	Working group staff
1530 - 1700	Recreation/Leisure Time	All other participants
1700 - 1830	Poster Session	All conference participants
1830 -	Dinner Activities/Recreation/Leisure Time	Participants to choose
1900 - 2200	Clinical-Neuroimaging-Pathology Symposium	Scientific Track participants

Friday, December 4 – Day 4
Hot Topics/Controversies/Harmonization

Time	Event/Title	Speaker/Participants
0700 - 0730	Breakfast	Participants
Session 13: Hot Topics		
Session Co-Chairs: Neill Graff-Radford, Mayo Clinic Florida; Zuzana Walker, University College London		
0730 - 0745	Can genetics assist in predicting the conversion from REM sleep behavior disorder to dementia with Lewy bodies and other synucleinopathies?	Ziv Gan-Or McGill University
0745 - 0800	Protein biomarkers in dementia with Lewy bodies	Neill Graff-Radford Mayo Clinic Florida
0800 - 0815	The influence of DLB feature and 123I-FP-CIT SPECT scan on diagnosis at 6-months follow-up	Zuzana Walker University College London
0815 - 0830	The SYNERGY Mouse: A model of bi-genic risk to develop dementia with Lewy bodies and parkinsonism	John Tomlinson University of Ottawa
0830 - 0900	<i>Break</i>	
Session 14: Controversies		
Session Co-Chairs: David Burn, Newcastle University; Daniel Weintraub, University of Pennsylvania		
0900 - 0915	Maintain the 1 year rule in PD/PDD and DLB: <i>Yes</i>	David Burn Newcastle University
0915 - 0930	Maintain the 1 year rule in PD/PDD and DLB: <i>No</i>	Ron Postuma McGill University
0930 - 0945	Discussion	Speakers and audience
0945 - 1000	Should antipsychotics be used in DLB? <i>Yes</i>	Clive Ballard King's College London
1000 - 1015	Should antipsychotics be used in DLB? <i>No</i>	Daniel Weintraub University of Pennsylvania
1015 - 1030	Discussion	Speakers and audience
1030 - 1100	<i>Break</i>	
Session 15: Toward Global DLB Research Harmonization		
Session Co-Chairs: Tom Montine, University of Washington; Dag Aarsland, Karolinska Institutet		
1100 - 1120	DLB research in North America	Tom Montine University of Washington
1120 - 1140	DLB research in Europe	Dag Aarsland Karolinska Institutet
1140 - 1200	DLB research in Asia	Hiroshige Fujishiro Nagoya University
1200 - 1220	Insights from the NACC for DLB Research	Walter Kukull University of Washington
1220 - 1245	Discussion	Speakers and audience
1245 - 1330	<i>Lunch</i>	
Session 16: Working Groups or Leisure Time/Farewell		
1330 - 1600	All Working Group Discussion	Working group staff
1330 -	Leisure time/Farewell	All other conference participants